Impact of generic antiretroviral drugs introduction on pharmaceutical expenditure patterns in the Netherlands: a six-year retrospective database analysis from 2016 to 2022
Our analysis showed high compliance with generic substitution of ARVs in the Netherlands. The increased use of generic ARVs was accompanied by an almost 10% reduction in overall expenditure on ART despite a significant increase in the number of patients in care in the Netherlands during this period. A significant contributing factor to ART costs appears to be the high percentage of prescribed patented Single-Tablet Regimens (STRs). These findings underscore the complex dynamics of pharmaceutical expenditures in the Dutch healthcare system.
Authors
- Matthijs van Luin (ORCID: https://orcid.org/0000-0001-8409-9316)
- Joost W. Vanhommerig (ORCID: https://orcid.org/0000-0002-3776-662X)
- David Marinus Burger (ORCID: https://orcid.org/0000-0001-7279-2818)
- Piter Oosterhof (ORCID: https://orcid.org/0009-0009-1551-7524)
- Kees Brinkman (ORCID: https://orcid.org/0009-0005-4791-1279)
Institutions
- Radboud University Nijmegen (NL)
- Radboud University Medical Center (NL)
- University Medical Center Utrecht (NL)
- OLVG (NL)
- Netherlands Institute for Health Services Research (NL)
- Radboud Institute for Molecular Life Sciences (NL)
- Meander Medisch Centrum (NL)
Publication Details
- Journal
- BMC Health Services Research
- Published
- 2025-05-04
- DOI
- https://doi.org/10.1186/s12913-025-12816-4
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00